Guerbet leads entry into UK market with magnetic resonance imaging (MRI) agents
This article was originally published in Clinica
French contrast agent manufacturer Guerbet has formed a UK subsidiary through which it will sell products directly to the market. The London-based operation, which will be headed by Francois Gary, will start up in the autumn and will initially sell MRI agents, Gullan Agerbak, director of the company's international subsidiaries division, told Clinica at the Rontgen Centenary congress in Birmingham last week.
You may also be interested in...
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.